Member Info for optrade

You are all welcome here, Good luck to you all :)

There are many shares on AIM with a depressed SP but not so many do 300% on a contact win, that is why it hurts to see it come down; but if you are smart and trust in tooples business model then top up for the win.
If you think the CEO is fake then look elsewhere.

Look at the big picture folks the SP is up compared to a month ago and I see two recent 15k buys.
What's the problem? Is it too volatile for you? This is AIM folks, only risk what you can afford to lose and take your profits on any decent rise.

I already explained, Toople needed a good cash top up and the banks needed collateral so they did a placing based on the SP only a few weeks ago which @ .3p was about right.

Miss G, I think you are underestimating the growth that is happening, listen to yesterdays CEO podcast again.

too risky for banks, with 10-20% daily swings not for the faint hearted !

The CEO has indicated that they should have enough cash from the placing to see them trough to cash positive.
There is obviously a positive momentum with toople which I don't believe will suddenly stop, business is very good.
and new contracts will keep coming in. If you want to sit on the fence and hate the CEO for not caring about shareholders don't say I didn't warn you when it bounces back.
The over-subscribers and others are taking the SP correction as a strong buying opportunity, the MM's are also involved, this is AIM.

Exactly the placing price was most probably based on the SP before the big contact news rise.
I'm sad for those that brought in at the top but with a little patience and more good contracts it should recover so hold/buy is my opinion.

well above .5p they could have got more than .3p imo.

Even if there is a future placing it will most likely be will above .5P
It's not unusual for high growth companies to need cash, if the CEO is right they now have enough to become cash positive.

Because this is one of the top UK tech growth companies, your concerns even if right won't hold back investors on future positive contract news which seems to be inevitable at the current rate.
There are still plenty buyers today. (most reported as sells)

SP is still up compared to a month ago, if others can not wait or live with the turbulence they shouldn't be here. It could easily pull back 50% in the next month or two so its a good buying opportunity in my opinion..
What will happen on the next decent contract win, 200% +?

With increasing revenue and no more placings through to a cash positive position as stated by the CEO today.
Even with the disappointment of the over-subscribed placing price, the company is doing very well and expanding fast.
Not a lot of downside from here as they continue to win new contracts so I rate this stock a buy.

Outlook for the current year ended 31 March 2019

Quote: "As a result of this likely deferment of expected income from the prior year, the first quarter of the year to 31 March 2019 is expected to benefit from an additional net profit of approximately £200,000. Furthermore, with visibility on other projects and growing recurring revenue streams, the Board expects considerable year on year improvement in the results for the 6 months to 30 September 2018.

The improvement in profitability in the current period at Group level has led to a consequent increase in cash in hand."

Results due end of month, SP could be very cheap at current prices.

You can pick these up for under 2.0P

The smart investors will pick some up while the SP is low, this has great potential upside and could jump to 0.5P when the news comes.

CEO recent result statement: " The past year was transformational for the Company in terms of a step change in scale, product and technology breadth, and organisational development. This has given us a strong foundation as we continue to make progress in the current financial year, with clear and specific strategic initiatives, an engaged management team and a shared vision: to become the industry's first choice for regenerative biomaterials."

This report should help quote: Underlying sales growth for 2016, at +74%, was an exceptional performance and ahead of expectations 2016 was transformational for COS, the new leadership team has realigned strategy onto an accelerated growth platform, whilst maintaining core objectives. Investment in new opportunities (China JV and Orthomimetics) continues to build a pipeline of strategic relationships that should drive long term growth, whilst delivering short term financial objectives. COS is also establishing a pipeline of finished devices, such as ChondroMimetic, to add incremental value to the business. These initiatives are enhancing significantly the value of the company which is NOT being reflected in the current share price. All good stuff, a potential boom stock!

Looks very undervalued so I picked up some, had to pay 8.75P

Ahead of market expectations,